Latest Cell Therapy News

Page 7 of 9
Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.
Ada Torres
Ada Torres
4 June 2025
AdAlta Limited has successfully raised $1.1 million through a renounceable rights issue, positioning itself to advance key CAR-T licensing and immunotherapy projects. The capital injection underscores confidence from leadership and investors amid a transformative phase for the biotech company.
Ada Torres
Ada Torres
3 June 2025
Prescient Therapeutics has reached a pivotal milestone by dosing the first patient in its Phase 2a clinical trial of PTX-100 for relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), aiming to evaluate safety and efficacy across multiple international sites.
Ada Torres
Ada Torres
27 May 2025
Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy clinical trial to Dose Level 2 after completing Dose Level 1 with no safety concerns, showing encouraging early signs of activity in advanced gastrointestinal cancers.
Ada Torres
Ada Torres
21 May 2025
Chimeric Therapeutics has raised $6.6 million through a discounted two-tranche placement to accelerate its promising CAR-T and NK cell therapy clinical programs. The capital raise, strongly backed by institutional and professional investors, signals growing confidence in the company’s oncology pipeline.
Ada Torres
Ada Torres
20 May 2025
Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.
Ada Torres
Ada Torres
16 May 2025
Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.
Ada Torres
Ada Torres
15 May 2025
Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.
Ada Torres
Ada Torres
15 May 2025
PolyNovo’s NovoSorb BTM technology has demonstrated promising first-in-human results as a novel delivery platform for pancreatic islet cell transplants in Type 1 diabetes, potentially redefining treatment approaches.
Ada Torres
Ada Torres
13 May 2025
AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.
Ada Torres
Ada Torres
5 May 2025
AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.
Ada Torres
Ada Torres
1 May 2025
Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.
Ada Torres
Ada Torres
30 Apr 2025